Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential
about
Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3.Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.Application of metabolomics in thyroid cancer research.Do sonographic and cytological features predict malignancy in cytologically indeterminate thyroid nodules?Pathologic diagnosis of papillary thyroid carcinoma: today and tomorrow.Galectin-3 and Cyclin D3 Immunohistochemistry and Tumor Dimensions Are Useful in Distinguishing Follicular Oncocytic Carcinomas from Oncocytic Adenomas of the Thyroid.Molecular classification and biomarker discovery in papillary thyroid carcinoma.Serum Galectin-3: diagnostic value for papillary thyroid carcinoma.Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesionsLarge needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology.CD56, HBME-1 and cytokeratin 19 expressions in papillary thyroid carcinoma and nodular thyroid lesionsThyroid tumor marker genomics and proteomics: diagnostic and clinical implications.Advances in cellular therapy for the treatment of thyroid cancer.Encapsulated papillary thyroid carcinoma, follicular variant: a misnomer.Highlighting nuclear membrane staining in thyroid neoplasms with emerin: review and diagnostic utility.Cytopathological review of patients that underwent thyroidectomies based on the diagnosis of papillary thyroid carcinoma by fine needle aspiration cytology but were later found to have benign tumors by histopathology.Diagnosis and management of differentiated thyroid cancer using molecular biology.Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.Evolution of the histologic classification of thyroid neoplasms and its impact on clinical management.Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: Historical Context, Diagnosis, and Future Challenges.Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.Cellular cohesiveness in benign and malignant thyroid follicular tumours varies significantly, but the difference is not useful in diagnosis of individual cases.Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV.Lack of BRAF mutations in hyalinizing trabecular neoplasm.The use of the Bethesda terminology in thyroid fine-needle aspiration results in a lower rate of surgery for nonmalignant nodules: a report from a reference center in Turkey.Utility of immunohistochemical markers in diagnosis of follicular cell derived thyroid lesions.Galectin-3: The Impact on the Clinical Management of Patients with Thyroid Nodules and Future Perspectives.Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a review for pathologists.Comparing Clinicopathologic and Radiographic Findings Between TT-UMP, Classical, and Non-Encapsulated Follicular Variants of Papillary Thyroid Carcinomas.Cells of Benign and Borderline Thyroid Tumor Express Malignancy Markers.Value of cytokeratin-19, Hector Battifora mesothelial-1 and galectin-3 immunostaining in the diagnosis of thyroid neoplasms.Galectin-3 and HBME-1 improve the accuracy of core biopsy in indeterminate thyroid nodules
P2860
Q33385643-EC7275EF-AB26-4FA8-8DF2-194844CB86C1Q35532196-D6B39897-B684-498C-AA06-2CF2D180970AQ35564078-F5AB7163-EA1D-4606-B732-84003F0E35C5Q36002073-3D294876-2E89-4E5F-8343-02ED436A009AQ36192721-79BE7F88-ADBC-481E-BB55-65082EB07B22Q36271908-CA6BDE01-0B58-4C70-8C07-9F34DEC4FC27Q36299916-F1E51ED4-810D-4812-ACE7-C0C802340208Q36358669-3CE93AF5-DAE6-4C77-8D15-748C2DA3E252Q36576631-D108FB53-544B-4E88-91C3-F0F02C212C41Q36612077-B7CF6978-C52D-4EC8-A227-A02382800246Q37436309-0BB78DF2-A519-4C93-813A-67A31F6003F8Q37767679-94E0E118-C784-4A4B-8289-86AD74114FFAQ37776660-F9D4C9D5-E9FE-468E-ADBB-EEFF2908A063Q37987579-0B2DDD11-00DD-405B-B093-008745C8880DQ38014369-5BBF3660-31CC-473B-9C10-FE7FF8FC2DF6Q38053115-5C43E44D-14DE-4DDE-AF31-7DA618013569Q38081125-07494A00-6E8C-419A-B925-B545D5A20594Q38404012-3527800F-B494-47A3-8250-A148261F52FBQ38677660-D0A3AC0A-A3B7-478D-B4CF-77B8EB280961Q38737374-6A94FD81-F5C6-4CE3-8CEB-AF256B5D35B5Q39363188-BF3DB0FF-9ADB-4E22-B9A8-2CBFA3ADB921Q39965066-FF6A0D92-5B66-40BA-909B-F760E15038CDQ41775650-975EFAC7-0337-4938-A038-E3F2CD294EC5Q42721155-5595B40B-D931-4CE4-B71A-91F088A93A40Q45342783-CC24651B-6511-42E5-9614-EA1B3E84FA07Q46539617-903EFBE0-499C-4F9F-9948-91C967A976F9Q47696912-FC728965-CBC3-4A49-AEFB-63210A82CC6BQ47754967-022808F3-930E-4F23-AEBB-D49B23AC6A61Q53089761-84B647E0-D9CA-4409-9487-C3B74055B28BQ53135128-DD2F9786-EB23-4B52-9899-014BD823C26DQ55262043-3FB28F1D-0AAE-4455-86C1-51609D1DEA12Q58005853-B9B71678-6F19-49E2-8162-60F12E13DA83
P2860
Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Galectin-3 and HBME-1 expressi ...... uncertain malignant potential
@ast
Galectin-3 and HBME-1 expressi ...... uncertain malignant potential
@en
Galectin-3 and HBME-1 expressi ...... uncertain malignant potential
@nl
type
label
Galectin-3 and HBME-1 expressi ...... uncertain malignant potential
@ast
Galectin-3 and HBME-1 expressi ...... uncertain malignant potential
@en
Galectin-3 and HBME-1 expressi ...... uncertain malignant potential
@nl
prefLabel
Galectin-3 and HBME-1 expressi ...... uncertain malignant potential
@ast
Galectin-3 and HBME-1 expressi ...... uncertain malignant potential
@en
Galectin-3 and HBME-1 expressi ...... uncertain malignant potential
@nl
P2093
P2860
P3181
P1433
P1476
Galectin-3 and HBME-1 expressi ...... uncertain malignant potential
@en
P2093
Juan Rosai
Mauro Papotti
Roberta De Pompa
P2860
P2888
P304
P3181
P356
10.1038/MODPATHOL.3800321
P407
P577
2005-04-01T00:00:00Z
P5875
P6179
1035698729